ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
수포성 표피 박리증 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 7.3%로 성장할 전망이며, 45억 9,000만 달러로 성장이 예측됩니다. 예측 기간 중의 성장은, 재생 의료 및 줄기세포 치료의 채용 증가, 인지도 및 진단율 향상, 유전자 치료 및 세포 치료의 승인 확대, 창상 치료 확대, 진단 증례 증가 등에 기인하고 있습니다. 이 기간 주요 동향으로는 신규 치료, 줄기세포 치료, 유전자 편집 기술, 표적 치료, 전략적 제휴, 유전자 연구의 진전 등을 들 수 있습니다.
수포성 표피 박리증 시장의 성장은 연구개발 활동의 활성화에 의해 견인될 것으로 예측됩니다. 이러한 활동에는 신제품, 프로세스, 기술 혁신, 개선, 창조하기 위한 체계적인 대처가 포함됩니다. 연구 개발 증가는 복잡한 질환에 대처하기 위한 혁신적인 치료법, 선진적인 치료법, 정밀 의료에 대한 수요의 고조에 기인하고 있습니다. 그 결과 이러한 노력은 진단, 관리 그리고 표피 수포증을 가진 사람들의 전체적인 삶의 질을 향상시키는 새로운 치료법, 선진적인 창상 케어 솔루션, 잠재적인 유전자 및 세포 기반 치료법의 발견으로 이어지고 있습니다. 예를 들어 2024년 4월 영국 국가통계국은 정부의 연구개발비(EU 거출금 제외)가 2021년 173억 달러에서 2022년 10.5% 증가한 약 192억 달러가 될 것이라고 보고했습니다. 그 결과, 연구 개발 활동의 고조가 시장의 성장에 기여하고 있습니다.
수포성 표피 박리증 시장의 기업은 장기적인 효능과 환자 결과의 개선을 목표로 하는 재이용 가능한 유전자 치료 등의 혁신에 점점 주력하고 있습니다. 기존의 일회성 유전자 치료와 달리 재사용 가능한 유전자 치료는 여러 번 투여함으로써 치료 효과를 유지 및 향상시킬 수 있습니다. 예를 들어, 2023년 5월 미국에 본사를 둔 생명공학 기업인 Krystal Biotech는 생후 6개월 이상의 디스트로피 표피 수포증(DEB)을 치료하기 위한 재사용 가능한 유전자 치료제인 VYJUVEK를 FDA가 승인했다고 발표했습니다. VYJUVEK는 COL7A1 유전자의 기능적 사본을 투여하여 DEB의 근본적인 유전적 결함에 대처합니다. 이 국소 요법은 기존의 치료법보다 저침습으로 간편한 대체 요법이며, 환자의 케어와 이용 편의성을 향상시킬 수 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 수포성 표피 박리증 시장 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 수포성 표피 박리증 시장 : 성장률 분석
세계의 수포성 표피 박리증 시장 실적 : 규모 및 성장(2019-2024년)
세계의 수포성 표피 박리증 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 수포성 표피 박리증 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 수포성 표피 박리증 시장 : 제품 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
항생제
진통제
기타
세계의 수포성 표피 박리증 시장 : 투여 방법별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
주사
경구
기타
세계의 수포성 표피 박리증 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원
홈케어
전문 클리닉
기타
세계의 수포성 표피 박리증 시장 : 항생 물질 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
국소 항생제
경구 항생제
주사용 항생제
세계의 수포성 표피 박리증 시장 : 진통제 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
NSAID
오피오이드
국소진통제
세계의 수포성 표피 박리증 시장 : 기타 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
상처 피복재
면역요법
유전자 치료
제7장 지역별 및 국가별 분석
세계의 수포성 표피 박리증 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 수포성 표피 박리증 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
수포성 표피 박리증 시장 : 경쟁 구도
수포성 표피 박리증 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
CHIESI Farmaceutici SpA : 개요, 제품 및 서비스, 전략 및 재무 분석
Shionogi Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
LEO Pharma A/S : 개요, 제품 및 서비스, 전략 및 재무 분석
BridgeBio Pharma Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Amicus Therapeutics Inc.
Amryt Pharma plc
Krystal Biotech Inc.
Castle Creek Biosciences Inc.
C4U Corporation
RHEACELL GmbH & Co. KG
Aegle Therapeutics Corp.
BioMendics LLC
InMed Pharmaceuticals Inc.
BPGbio Inc.
ProQR Therapeutics NV
Holostem Terapie Avanzate Srl
TWi Biotechnology Inc.
Abeona Therapeutics Inc.
RegeneRx Biopharmaceuticals Inc.
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
수포성 표피 박리증 시장(2029년) : 새로운 기회를 제공하는 국가
수포성 표피 박리증 시장(2029년) : 새로운 기회를 제공하는 부문
수포성 표피 박리증 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
Epidermolysis bullosa (EB) refers to a group of rare genetic disorders that result in extremely fragile skin, causing blistering and wounds from even minor friction or trauma. These conditions are important for studying genetic skin diseases, advancing wound care treatments, and developing innovative gene and cell therapies to improve patient outcomes.
The main product types for epidermolysis bullosa include antibiotics, analgesics, and other treatments. Antibiotics are medications used to treat bacterial infections by either killing bacteria or inhibiting their growth. These medications are administered through various methods, including injectables, oral treatments, and others. They are used by various end users, such as hospitals, home care providers, specialty clinics, and more.
The epidermolysis bullosa market research report is one of a series of new reports from The Business Research Company that provides epidermolysis bullosa market statistics, including the epidermolysis bullosa industry global market size, regional shares, competitors with the epidermolysis bullosa market share, detailed epidermolysis bullosa market segments, market trends, and opportunities, and any further data you may need to thrive in the epidermolysis bullosa industry. This epidermolysis bullosa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The epidermolysis bullosa market size has grown strongly in recent years. It will grow from $3.22 billion in 2024 to $3.46 billion in 2025 at a compound annual growth rate (CAGR) of 7.6%. The growth during the historic period can be attributed to the rise in clinical trials, the increasing prevalence of epidermolysis bullosa, greater awareness, and a surge in research funding. Additionally, there has been an increasing focus on gene therapy and the treatment of rare diseases.
The epidermolysis bullosa market size is expected to see strong growth in the next few years. It will grow to $4.59 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%. The growth during the forecast period can be attributed to the rising adoption of regenerative medicine and stem cell therapy, increased awareness and diagnosis rates, growing approvals of gene and cell therapies, expanding wound care, and a rise in diagnosed cases. Key trends during this period include novel therapies, stem cell treatments, gene editing technology, targeted therapies, strategic collaborations, and advancements in genetic research.
The growth of the epidermolysis bullosa market is expected to be driven by the increasing activities in research and development. These activities involve systematic efforts to innovate, improve, or create new products, processes, or technologies. The rise in research and development can be attributed to the growing demand for innovative treatments, advanced therapies, and precision medicine to tackle complex diseases. As a result, these efforts are leading to the discovery of novel therapies, advanced wound care solutions, and potential gene and cell-based treatments that improve diagnosis, management, and the overall quality of life for those with epidermolysis bullosa. For example, in April 2024, the Office for National Statistics in the UK reported that the government's research and development spending (excluding EU contributions) rose by 10.5% to approximately $19.2 billion in 2022, up from $17.3 billion in 2021. Consequently, the rising emphasis on research and development is contributing to the market's growth.
Companies in the epidermolysis bullosa market are increasingly focusing on innovations such as redosable gene therapy, which aims to improve long-term efficacy and patient outcomes. Unlike traditional one-time gene therapies, redosable gene therapy can be administered multiple times to maintain or enhance its therapeutic effects. For instance, in May 2023, Krystal Biotech Inc., a U.S.-based biotechnology firm, announced that the FDA had approved VYJUVEK, a redosable gene therapy for treating dystrophic epidermolysis bullosa (DEB) in patients aged six months and older. VYJUVEK delivers a functional copy of the COL7A1 gene to address the underlying genetic defect of DEB. This topical therapy provides a less invasive and more convenient alternative to traditional treatments, improving patient care and accessibility.
In August 2023, Paradigm Therapeutics Inc., a U.S.-based biopharmaceutical company, acquired the global rights to SD-101 from Amicus Therapeutics for an undisclosed amount. Through this acquisition, Paradigm Therapeutics aims to further the development of this breakthrough therapy, which is designed to treat all subtypes of epidermolysis bullosa. This move is intended to accelerate the potential of SD-101 as a groundbreaking treatment solution for patients with the condition. Amicus Therapeutics, known for its focus on gene therapies, wound care, and innovative drugs for epidermolysis bullosa, was instrumental in developing this therapeutic approach.
Major players in the epidermolysis bullosa market are Pfizer Inc., CHIESI Farmaceutici S.p.A, Shionogi Inc., LEO Pharma A/S, BridgeBio Pharma Inc., Amicus Therapeutics Inc., Amryt Pharma plc, Krystal Biotech Inc., Castle Creek Biosciences Inc., C4U Corporation, RHEACELL GmbH & Co. KG, Aegle Therapeutics Corp., BioMendics LLC, InMed Pharmaceuticals Inc., BPGbio Inc., ProQR Therapeutics N.V., Holostem Terapie Avanzate Srl, TWi Biotechnology Inc., Abeona Therapeutics Inc., and RegeneRx Biopharmaceuticals Inc.
North America was the largest region in the epidermolysis bullosa market in 2024. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the epidermolysis bullosa market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The epidermolysis bullosa market consists of sales of wound care dressings, topical creams, gene therapy products, skin grafts, and pain management medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Epidermolysis Bullosa Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on epidermolysis bullosa market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for epidermolysis bullosa ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The epidermolysis bullosa market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Product Type: Antibiotic; Analgesics; Other Product Types
2) By Mode Of Administration: Injectables; Oral; Other Modes of Administration
3) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
Subsegments:
1) By Antibiotic: Topical Antibiotics; Oral Antibiotics; Injectable Antibiotics
2) By Analgesics: NSAIDs; Opioids; Topical Pain Relievers
3) By Other Product Types: Wound Dressings; Immunotherapies; Gene Therapies
Companies Mentioned: Pfizer Inc.; CHIESI Farmaceutici S.p.A; Shionogi Inc.; LEO Pharma A/S; BridgeBio Pharma Inc.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Epidermolysis Bullosa Market Characteristics
3. Epidermolysis Bullosa Market Trends And Strategies
4. Epidermolysis Bullosa Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Epidermolysis Bullosa Growth Analysis And Strategic Analysis Framework
5.1. Global Epidermolysis Bullosa PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Epidermolysis Bullosa Market Growth Rate Analysis
5.4. Global Epidermolysis Bullosa Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Epidermolysis Bullosa Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Epidermolysis Bullosa Total Addressable Market (TAM)
6. Epidermolysis Bullosa Market Segmentation
6.1. Global Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antibiotic
Analgesics
Other Product Types
6.2. Global Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Injectables
Oral
Other Mode Of Administrations
6.3. Global Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Homecare
Specialty Clinics
Other End Users
6.4. Global Epidermolysis Bullosa Market, Sub-Segmentation Of Antibiotic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Topical Antibiotics
Oral Antibiotics
Injectable Antibiotics
6.5. Global Epidermolysis Bullosa Market, Sub-Segmentation Of Analgesics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
NSAIDs
Opioids
Topical Pain Relievers
6.6. Global Epidermolysis Bullosa Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Wound Dressings
Immunotherapies
Gene Therapies
7. Epidermolysis Bullosa Market Regional And Country Analysis
7.1. Global Epidermolysis Bullosa Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Epidermolysis Bullosa Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Epidermolysis Bullosa Market
9.1. China Epidermolysis Bullosa Market Overview
9.2. China Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Epidermolysis Bullosa Market
10.1. India Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Epidermolysis Bullosa Market
11.1. Japan Epidermolysis Bullosa Market Overview
11.2. Japan Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Epidermolysis Bullosa Market
12.1. Australia Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Epidermolysis Bullosa Market
13.1. Indonesia Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Epidermolysis Bullosa Market
14.1. South Korea Epidermolysis Bullosa Market Overview
14.2. South Korea Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Epidermolysis Bullosa Market
15.1. Western Europe Epidermolysis Bullosa Market Overview
15.2. Western Europe Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Epidermolysis Bullosa Market
16.1. UK Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Epidermolysis Bullosa Market
17.1. Germany Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Epidermolysis Bullosa Market
18.1. France Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Epidermolysis Bullosa Market
19.1. Italy Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Epidermolysis Bullosa Market
20.1. Spain Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Epidermolysis Bullosa Market
21.1. Eastern Europe Epidermolysis Bullosa Market Overview
21.2. Eastern Europe Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Epidermolysis Bullosa Market
22.1. Russia Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Epidermolysis Bullosa Market
23.1. North America Epidermolysis Bullosa Market Overview
23.2. North America Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Epidermolysis Bullosa Market
24.1. USA Epidermolysis Bullosa Market Overview
24.2. USA Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Epidermolysis Bullosa Market
26.1. South America Epidermolysis Bullosa Market Overview
26.2. South America Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Epidermolysis Bullosa Market
27.1. Brazil Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Epidermolysis Bullosa Market
28.1. Middle East Epidermolysis Bullosa Market Overview
28.2. Middle East Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Epidermolysis Bullosa Market
29.1. Africa Epidermolysis Bullosa Market Overview
29.2. Africa Epidermolysis Bullosa Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Epidermolysis Bullosa Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Epidermolysis Bullosa Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Epidermolysis Bullosa Market Competitive Landscape And Company Profiles
